Individuals who regularly use pain reliever aspirin are likely to experience a significant reduction in digestive cancer risk finds a study involving over 600000 people. The findings showed that patients who were prescribed aspirin daily showed a 47 percent reduction in liver and oesophageal cancer incidence. Gastric cancer reduced by 38 percent pancreatic cancer by 34 percent while colorectal cancer by 24 percent it said. Digestive cancers account for almost a quarter of cancer cases in Europe. Colorectal gastric and pancreatic cancer are the top five cancer killers throughout the continent with digestive cancers representing 30.1 percent of cancer deaths.